Cargando…

Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab

Detalles Bibliográficos
Autores principales:	Buttgereit, Thomas, Grekowitz, Eva Maria, Metz, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350330/ https://www.ncbi.nlm.nih.gov/pubmed/34401426 http://dx.doi.org/10.1016/j.jdcr.2021.06.028

Ejemplares similares

Dupilumab for cancer-associated refractory pruritus
por: Talmon, Aviv, et al.
Publicado: (2023)

Interleukin-31 and Chronic Pruritus of Unknown Origin
por: Salao, Kanin, et al.
Publicado: (2020)

Chronic Pruritus Responding to Dupilumab—A Case Series
por: Zhai, Lisa L., et al.
Publicado: (2019)

Refractory pruritus responds to dupilumab in a patient with TTC7A mutation
por: Alipour Tehrany, Yassaman, et al.
Publicado: (2020)

Chronic Pruritus of Unknown Origin: Clinical Profile and Disease-Related Burden
por: PEREIRA, Manuel P., et al.
Publicado: (2021)

Six cases of refractory pruritus and histologic dermal hypersensitivity reaction successfully treated with dupilumab
por: Edmonds, Nicole, et al.
Publicado: (2021)

Recalcitrant anal and genital pruritus treated with dupilumab()()()()
por: Yang, E.J., et al.
Publicado: (2018)

The use of dupilumab for the treatment of recalcitrant brachioradial pruritus
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Dupilumab Failure in Treating Dermatomyositis-Associated Pruritus
por: O'Brien, Margaret A, et al.
Publicado: (2022)

Pruritus Vulvæ Relieved by Iodide of Potassium
Publicado: (1881)

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study
por: Mastorino, Luca, et al.
Publicado: (2021)

Truncal Pruritus of Unknown Origin May Be a Symptom of Diabetic Polyneuropathy
por: Yamaoka, Hiroyuki, et al.
Publicado: (2010)

Aprepitant for the Treatment of Chronic Refractory Pruritus
por: He, Alice, et al.
Publicado: (2017)

Efficacy of the Multi-Target Compound E153 in Relieving Pain and Pruritus of Different Origins
por: Mogilski, Szczepan, et al.
Publicado: (2023)

Upadacitinib as a treatment for chronic pruritus secondary to polycythemia vera after failure with dupilumab
por: Wachuku, Christopher I., et al.
Publicado: (2023)

A successful case of dupilumab treatment for severe uremic pruritus
por: Silverberg, Jonathan I., et al.
Publicado: (2019)

Dupilumab Improves Pruritus in Netherton Syndrome: A Case Study
por: Inaba, Yutaka, et al.
Publicado: (2022)

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab
por: Kazemi, Soroush, et al.
Publicado: (2022)

Efficacy of pregabalin for the treatment of chronic pruritus of unknown origin, assessed based on electric current perception threshold
por: Lee, JaeIn, et al.
Publicado: (2020)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Incidental improvement of programmed cell death-1 receptor inhibitor-induced vitiligo after initiation of dupilumab therapy for refractory pruritus
por: Robinson, Warner, et al.
Publicado: (2023)

Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients
por: Mastorino, Luca, et al.
Publicado: (2022)

Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
por: Cai, Lu, et al.
Publicado: (2023)

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
por: Han, Yuyang, et al.
Publicado: (2022)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Immunoglobulin G4-Related Disease-Associated Dermatitis with Pruritus: A Positive Response to Dupilumab
por: Beck, Tyler C., et al.
Publicado: (2023)

Evaluation of apremilast in chronic pruritus of unknown origin: A proof‐of‐concept, phase 2a, open‐label, single‐arm clinical trial
por: Clark, Marie, et al.
Publicado: (2020)

In vivo imaging of patients with chronic pruritus of unknown origin reveals partial sweat duct obstruction with partial itch resolution upon retinoid treatment
por: Lim, Shi Yu Derek, et al.
Publicado: (2023)

Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
por: Sun, Ziyi, et al.
Publicado: (2023)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

Combination treatment of dupilumab with bortezomib in a patient with IgG kappa gammopathy of renal significance, uremic pruritus and chronic lichenoid dermatitis
por: Paolino, Giovanni, et al.
Publicado: (2023)

Original Research Work on Pruritus Ani
por: Murray, Dwight H.
Publicado: (1917)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023)

Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis
por: Di Staso, Federico, et al.
Publicado: (2022)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab
por: Gangadharan Nambiar, Gopinathan, et al.
Publicado: (2022)

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid
por: WANG, Qijun, et al.
Publicado: (2023)

Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis
por: Wang, Zhaoling, et al.
Publicado: (2022)

Plasmapheresis for Refractory Pruritus due to Drug-Induced Cholestasis
por: Al-Azzawi, Hasan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_37rf7lcvu7ff6ru7o4ls2j7hbg